Global Oncology Academy - Global Oncology Academy

Global Oncology Academy

Global Oncology Academy

Enhance your practice with CME
and tools that focus on the management
and treatment of patients with cancer.

Popular

Improving Long-Term Adherence to CRC Screening Recommendations
Improving Long-Term Adherence to CRC Screening Recommendations
Clinician's Roundtable
Improving Long-Term Adherence to CRC Screening Recommendations
Brian P. McDonough, MD, FAAFP; David A. Lieberman, MD
- Brian P. McDonough, MD, FAAFP
- David A. Lieberman, MD
Evidence-Based Care for PD-L1-Negative Non-Small Cell Lung Cancer
Evidence-Based Care for PD-L1-Negative Non-Small Cell Lung Cancer
Project Oncology®
Evidence-Based Care for PD-L1-Negative Non-Small Cell Lung Cancer
Steve Jackson, PharmD; Apar Kishor Ganti, MD
- Steve Jackson, PharmD
- Apar Kishor Ganti, MD
- Thomas Marron, MD, PhD
MinuteCE®
Treatment Decisions That Matter: A Case-Based Discussion in Advanced Ovarian Cancer
Kathleen N. Moore, MD; Ritu Salani, MD
1.00 credit 5 episodes
- Kathleen N. Moore, MD
- Ritu Salani, MD
1.00 credit 5 episodes
Case Consult: Treatment Strategies for HER2-Positive Platinum-Resistant Ovarian Cancer
Case Consult: Treatment Strategies for HER2-Positive Platinum-Resistant Ovarian Cancer
MinuteCE®
Case Consult: Treatment Strategies for HER2-Positive Platinum-Resistant Ovarian Cancer
Kathleen N. Moore, MD; Ritu Salani, MD
1.00 program credit
- Kathleen N. Moore, MD
- Ritu Salani, MD
1.00 program credit
Case Consult: Targeting CDH6 in Platinum-Resistant Ovarian Cancer
Case Consult: Targeting CDH6 in Platinum-Resistant Ovarian Cancer
MinuteCE®
Case Consult: Targeting CDH6 in Platinum-Resistant Ovarian Cancer
Kathleen N. Moore, MD; Ritu Salani, MD
1.00 program credit
- Kathleen N. Moore, MD
- Ritu Salani, MD
1.00 program credit
Case Consult: Treatment Strategies for FRα-Positive Platinum-Resistant Ovarian Cancer
Case Consult: Treatment Strategies for FRα-Positive Platinum-Resistant Ovarian Cancer
MinuteCE®
Case Consult: Treatment Strategies for FRα-Positive Platinum-Resistant Ovarian Cancer
Kathleen N. Moore, MD; Ritu Salani, MD
1.00 program credit
- Kathleen N. Moore, MD
- Ritu Salani, MD
1.00 program credit
CME/CE Virtual Event
Closing the Gap in First-Line Treatment of KRAS G12C–Mutated Advanced NSCLC: From Biology to Bedside Decisions and Trial-Ready Care
Multiple dates available
0.75 credits
Current Approaches to Advanced Urothelial Carcinoma
Current Approaches to Advanced Urothelial Carcinoma
Project Oncology®
Current Approaches to Advanced Urothelial Carcinoma
Guru P. Sonpavde, MD
- Guru P. Sonpavde, MD

Medical News

Medical News
Mental Health Comorbidity Raises Acute Care Use in Cancer
08/17/2026
Read more
Medical News
BACE Added to Tislelizumab Improved Response in Bulky NSCLC
08/17/2026
Read more
Medical News
CT Body Composition Misses Cancer Nutritional Risk
08/17/2026
Read more
Medical News
SEER-22 Study Finds Mycosis Fungoides Survival Gaps
08/11/2026
Read more

CME/CE

Case Consult: Personalizing First-Line Maintenance Therapy in Advanced Ovarian Cancer
Case Consult: Personalizing First-Line Maintenance Therapy in Advanced Ovarian Cancer
MinuteCE®
Case Consult: Personalizing First-Line Maintenance Therapy in Advanced Ovarian Cancer
Kathleen N. Moore, MD; Ritu Salani, MD
1.00 program credit
- Kathleen N. Moore, MD
- Ritu Salani, MD
1.00 program credit
CME/CE In-Person & Virtual Event
The CELMoD Shift: Translating Protein Degradation Science Into Practice-Changing Myeloma Care
December 11, 2026
New Orleans, Louisiana
1.50 credits
Translating Research Into Practice in Breast Cancer: Emerging Data and the Expanding Role of ADCs
Translating Research Into Practice in Breast Cancer: Emerging Data and the Expanding Role of ADCs
CME/CE
Translating Research Into Practice in Breast Cancer: Emerging Data and the Expanding Role of ADCs
Sara A. Hurvitz, MD, FACP; Tiffany Traina, MD
0.50 credits
- Sara A. Hurvitz, MD, FACP
- Tiffany Traina, MD
0.50 credits
Rationale of Emerging Antigen-Directed Strategies in Frontline ES-SCLC
Rationale of Emerging Antigen-Directed Strategies in Frontline ES-SCLC
MinuteCE®
Rationale of Emerging Antigen-Directed Strategies in Frontline ES-SCLC
Neal Ready, MD, PhD
0.50 program credits
- Neal Ready, MD, PhD
0.50 program credits

Clinical Practice

CME/CE Virtual Event
Targeting TROP2 in EGFR-Mutated Advanced NSCLC: Navigating the ADC Revolution After TKI Failure
Multiple dates available
0.50 credits
Case Consult: PD-L1–Guided Treatment Decisions in Platinum-Resistant Ovarian Cancer
Case Consult: PD-L1–Guided Treatment Decisions in Platinum-Resistant Ovarian Cancer
MinuteCE®
Case Consult: PD-L1–Guided Treatment Decisions in Platinum-Resistant Ovarian Cancer
Kathleen N. Moore, MD; Ritu Salani, MD
1.00 program credit
- Kathleen N. Moore, MD
- Ritu Salani, MD
1.00 program credit
Real-World Outcomes with Axatilimab in cGVHD
Real-World Outcomes with Axatilimab in cGVHD
Project Oncology®
Real-World Outcomes with Axatilimab in cGVHD
Brian P. McDonough, MD, FAAFP; Hana Safah, MD
- Brian P. McDonough, MD, FAAFP
- Hana Safah, MD
Advanced Urothelial Carcinoma: Optimizing Second-Line Care
Advanced Urothelial Carcinoma: Optimizing Second-Line Care
Project Oncology®
Advanced Urothelial Carcinoma: Optimizing Second-Line Care
Guru P. Sonpavde, MD
- Guru P. Sonpavde, MD

Programs

Gastric Cancer Prevention: A Risk-Based Approach
Gastric Cancer Prevention: A Risk-Based Approach
GI Insights
Gastric Cancer Prevention: A Risk-Based Approach
Peter Buch, MD, FACG, AGAF, FACP; Chul Hyun, MD, PhD, MPH
- Peter Buch, MD, FACG, AGAF, FACP
- Chul Hyun, MD, PhD, MPH
Factors Guiding First-Line Treatment Decisions for Myelofibrosis and Anemia
Factors Guiding First-Line Treatment Decisions for Myelofibrosis and Anemia
Project Oncology®
Factors Guiding First-Line Treatment Decisions for Myelofibrosis and Anemia
Charles Turck, PharmD, BCPS, BCCCP; Douglas A. Tremblay, MD
- Charles Turck, PharmD, BCPS, BCCCP
- Douglas A. Tremblay, MD
Axatilimab’s Impact on cGVHD and Associated BOS
Axatilimab’s Impact on cGVHD and Associated BOS
Project Oncology®
Axatilimab’s Impact on cGVHD and Associated BOS
Charles Turck, PharmD, BCPS, BCCCP; Amandeep Salhotra, MD
- Charles Turck, PharmD, BCPS, BCCCP
- Amandeep Salhotra, MD
Can AI Imaging Improve Risk Stratification in Upper Tract Urothelial Carcinoma?
Can AI Imaging Improve Risk Stratification in Upper Tract Urothelial Carcinoma?
Project Oncology®
Can AI Imaging Improve Risk Stratification in Upper Tract Urothelial Carcinoma?